AI Article Synopsis
- The GENETIC-AF trial is a randomized, double-blinded study comparing bucindolol and metoprolol succinate for preventing atrial fibrillation (AF) in patients with heart failure and a specific genetic profile (ADRB1 Arg389Arg).
- Bucindolol, a non-selective beta-blocker, has shown potential benefits in heart failure patients with this genotype, but its effectiveness in preventing AF hasn't been validated through randomized trials until now.
- The study aims to enroll around 620 patients and will measure the time until recurrence of symptomatic AF or mortality, assessing the safety and effectiveness of bucindolol over 24 weeks.
Article Abstract
Background: Few therapies are available for the safe and effective treatment of atrial fibrillation (AF) in patients with heart failure. Bucindolol is a non-selective beta-blocker with mild vasodilator activity previously found to have accentuated antiarrhythmic effects and increased efficacy for preventing heart failure events in patients homozygous for the major allele of the ADRB1 Arg389Gly polymorphism (ADRB1 Arg389Arg genotype). The safety and efficacy of bucindolol for the prevention of AF or atrial flutter (AFL) in these patients has not been proven in randomized trials.
Methods/design: The Genotype-Directed Comparative Effectiveness Trial of Bucindolol and Metoprolol Succinate for Prevention of Symptomatic Atrial Fibrillation/Atrial Flutter in Patients with Heart Failure (GENETIC-AF) trial is a multicenter, randomized, double-blinded "seamless" phase 2B/3 trial of bucindolol hydrochloride versus metoprolol succinate, for the prevention of symptomatic AF/AFL in patients with reduced ejection fraction heart failure (HFrEF). Patients with pre-existing HFrEF and recent history of symptomatic AF are eligible for enrollment and genotype screening, and if they are ADRB1 Arg389Arg, eligible for randomization. A total of approximately 200 patients will comprise the phase 2B component and if pre-trial assumptions are met, 620 patients will be randomized at approximately 135 sites to form the Phase 3 population. The primary endpoint is the time to recurrence of symptomatic AF/AFL or mortality over a 24-week follow-up period, and the trial will continue until 330 primary endpoints have occurred.
Conclusions: GENETIC-AF is the first randomized trial of pharmacogenetic guided rhythm control, and will test the safety and efficacy of bucindolol compared with metoprolol succinate for the prevention of recurrent symptomatic AF/AFL in patients with HFrEF and an ADRB1 Arg389Arg genotype. (ClinicalTrials.govNCT01970501).
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ahj.2017.12.001 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prognostic value of left atrioventricular coupling index in heart failure.
Eur Heart J Cardiovasc Imaging
January 2025
Heart Institute, Department of Cardiology. Germans Trias i Pujol University Hospital, Barcelona,Spain.
Aims: To investigate the distribution of left atrioventricular coupling index (LACI) among patients with heart failure and left ventricular ejection fraction (LVEF)<50% and to explore its association with the combined endpoint of all-cause death or HF hospitalization at long term follow-up.
Methods And Results: Patients with HF and LVEF<50% undergoing cardiac magnetic resonance (CMR) were evaluated. Patients with atrial fibrillation or flutter were excluded.
Unsupervised clustering of intraventricular hemodynamic forces for the phenotyping of left-ventricular function in non-ischemic left ventricular cardiomyopathy.
Eur Heart J Cardiovasc Imaging
January 2025
Vall d'Hebron Research Institute (VHIR), Barcelona, Spain.
Background: Cardiac magnetic resonance (CMR) is essential for diagnosing cardiomyopathy, serving as the gold standard for assessing heart chamber volumes and tissue characterization. Hemodynamic forces (HDF) analysis, a novel approach using standard cine CMR images, estimates energy exchange between the left ventricular (LV) wall and blood. While prior research has focused on peak or mean longitudinal HDF values, this study aims to investigate whether unsupervised clustering of HDF curves can identify clinically significant patterns and stratify cardiovascular risk in non-ischemic LV cardiomyopathy (NILVC).
View Article and Find Full Text PDFMalignant hypertension induces thrombotic microangiopathy and renal failure: A case report.
Medicine (Baltimore)
January 2025
Faculty of Chinese Medicine, Macau University of Science and Technology, Taipa, Macau, China.
Rationale: Thrombotic microangiopathies (TMA) caused by malignant hypertension is an acute and critical disease among rare diseases. Although renal biopsy pathology is a golden indicator for diagnosing kidney disease, it cannot distinguish between primary and secondary TMA and requires a comprehensive diagnosis in conjunction with other laboratory tests and medical history.
Patient Concerns: A 33-year-old young man was hospitalized due to unexplained kidney failure.
Causal relationship between immune cells and heart failure: A Mendelian randomization study.
Medicine (Baltimore)
January 2025
The First Clinical College of Chinese Medicine, Hunan University of Chinese Medicine, Changsha, Hunan, China.
This study aimed to evaluate the causal effects of different immune cells on heart failure (HF) using Mendelian randomization (MR). Datasets for immune cell phenotypes and HF were obtained from European Bioinformatics Institute and FinnGen. Then, single nucleotide polymorphisms were screened according to the basic assumptions of MR.
View Article and Find Full Text PDFComparative Effectiveness of Bisoprolol, Carvedilol, and Metoprolol Succinate in Patients with Heart Failure and CKD.
Clin J Am Soc Nephrol
January 2025
Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, California.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!